tag cardiovascular-disease 
Rethinking Clinical Trials
DECEMBER 20, 2023
Globally cardiovascular disease (CVD) prevalence had decreased between 1990 and 2010, but it has slightly increased since 2010. Further efforts are urgently needed to increase diversity in the cardiology workforce, which will improve clinical trial diversity and cardiovascular health for all. years for males and 5.5
Rethinking Clinical Trials
JANUARY 23, 2024
People with angina-like symptoms are often not patients with a disease. Most do not have obstructive coronary artery disease (CAD), but a few are very high risk. They are trying to follow the guidelines for symptoms and disease. The tests are so common in aggregate it is a big expense. They are pretty good.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JANUARY 26, 2023
There is little question about the utility of LDL lowering as a means of cardiovascular risk reduction. The treatment is on-label because anyone with an acute coronary has at risk cardiovascular disease so technically it is on-label. This study is looking at a particular subpopulation, where there is a lack of outcomes data.
Rethinking Clinical Trials
JULY 19, 2023
The intervention included assessment of local practices and barriers, development of strategies to overcome those barriers, and audit and feedback of quality metrics, with the goal of improving the way clinics approach treatment of these diseases. However, these therapies are highly underused in routine clinical practice. Granger, MD; Neha J.
World of DTC Marketing
NOVEMBER 3, 2020
Cardiovascular disease deaths in the US have increased by nearly 17% since 2010, and are among the reasons that life expectancy in the U.S. The Global Burden of Disease study estimates that high sodium intake causes between 1 million and 5 million deaths per year globally” Then there is the obesity epidemic.
Rethinking Clinical Trials
OCTOBER 11, 2023
Murray, PhD NIH Associate Director for Prevention and Director, NIH Office of Disease Prevention Moderator: Jonathan C. Moyer, PhD Statistician, NIH Office of Disease Prevention Slides Keywords Implementation; Study design; Hybrid; Clustered; DECIPHeR Key Points People often contest that hybrid designs are not as rigorous as they should be.
Rethinking Clinical Trials
DECEMBER 6, 2022
Director, Cardiovascular and Metabolism Research, DCRI. Making lifestyle changes is difficult especially for people living with chronic diseases, where healthy behaviors could make a big difference. This study asks how can we better facilitate health behaviors in patients with chronic diseases and can we leverage technology?
Expert insights. Personalized for you.
169 
Let's personalize your content